In January, the U.S. approved its first primary-treatment generic AIDS med for the President’s $15 billion global AIDS initiative, PEPFAR.

Two Guatemalandemonstrators died March 15 when nationwide protests over theratification of a trade treaty that will restrict generic meds,including HIV meds, turned violent.

On March 16, Brazil threatened to break U.S. drug patents unless American drug companies shared drugmaking technology with local pharma factories.

In Kenya,where 77 percent of medicated HIVers take generics, hundreds ofprotesters rallied unsuccessfully March 18 against Indian anti-genericlegislation at Nairobi’s Indian High Commission.

Belgiangenerics company Propharex is sending a turnkey generics factorypiecemeal to the African nation of Gabon, aiming to boost production ofaffordable HIV meds.

On March 23, India tightenedits anti-generics legislation, possibly restricting generic productionof future AIDS meds but ensuring continued membership in the WorldTrade Organization.